retatrutide and perimenopause for Women Over 40: 25% Weight Loss Results Menopausal Transition (Perimenopause) | ReproductiveFacts.org

For now, we will have to take it by injection once a week

As of 2025, retatrutide has not received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for routine clinical use in the UK

Popular technologies include: Ultherapy (micro-focused ultrasound)

The primary mechanism involves stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, and slowing gastric emptying

Its simultaneous activation of three receptor pathways GLP-1R for appetite suppression and insulin secretion, GIPR for augmented insulin response and central appetite modulation, and GCGR for energy expenditure and hepatic fat mobilisation produces metabolic effects that exceed what single or dual agonism can achieve [4][8][9]

GLP-1 drugs alone produced $1.1 billion dollars in claims in 2024, more than a 29% increase from 2023